Search

Your search keyword '"Christoph Liebetrau, MD"' showing total 2 results
Start Over Author "Christoph Liebetrau, MD"
2 results on '"Christoph Liebetrau, MD"'

1. Exercise right heart catheterization before and after balloon pulmonary angioplasty in inoperable patients with chronic thromboembolic pulmonary hypertension

Author

Christoph B. Wiedenroth, MD, Andreas J. Rieth, MD, Steffen Kriechbaum, MD, H.-Ardeschir Ghofrani, MD, Andreas Breithecker, MD, Moritz Haas, MD, Fritz Roller, MD, Manuel J. Richter, MD, Mareike Lankeit, Lisa Mielzarek, Andreas Rolf, MD, Christian W. Hamm, MD, Eckhard Mayer, MD, Stefan Guth, MD, and Christoph Liebetrau, MD

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the respiratory system, RC705-779
Abstract

Background * These authors contributed equally as last authors. Balloon pulmonary angioplasty is an evolving, interventional treatment option for inoperable patients with chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary hypertension at rest as well as exercise capacity is considered to be relevant outcome parameters. The aim of the present study was to determine whether measurement of pulmonary hemodynamics during exercise before and six months after balloon pulmonary angioplasty have an added value. Methods From March 2014 to July 2018, 172 consecutive patients underwent balloon pulmonary angioplasty. Of these, 64 consecutive patients with inoperable CTEPH underwent a comprehensive diagnostic workup that included right heart catheterization at rest and during exercise before balloon pulmonary angioplasty treatments and six months after the last intervention. Results Improvements in pulmonary hemodynamics at rest and during exercise, in quality of life, and in exercise capacity were observed six months after balloon pulmonary angioplasty: WHO functional class improved in 78% of patients. The mean pulmonary arterial pressure (mPAP) at rest was reduced from 41 ± 9 to 31 ± 9 mmHg (p

Published
2020
Full Text
View/download PDF

2. Cardiac Myosin Binding Protein-C Autoantibodies Are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome

Author

Thomas L. Lynch, IVPhD, Diederik W.D. Kuster, PhD, Beverly Gonzalez, ScM, Neelam Balasubramanian, BA, Nandini Nair MD, PhD, Sharlene Day, PhD, Jenna E. Calvino, BA, Yanli Tan, RN, Christoph Liebetrau, MD, Christian Troidl, PhD, Christian W. Hamm, MD, Ahmet Güçlü, MD, Barbara McDonough, RN, Ali J. Marian, MD, Jolanda van der Velden, PhD, Christine E. Seidman, MD, Gordon S. Huggins, MD, and Sakthivel Sadayappan, PhD

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Summary: The degradation and release of cardiac myosin binding protein-C (cMyBP-C) upon cardiac damage may stimulate an inflammatory response and autoantibody (AAb) production. We determined whether the presence of cMyBP-C-AAbs associated with adverse cardiac function in cardiovascular disease patients. Importantly, cMyBP-C-AAbs were significantly detected in acute coronary syndrome patient sera upon arrival to the emergency department, particularly in ST-segment elevation myocardial infarction patients. Patients positive for cMyBP-C-AAbs had reduced left ventricular ejection fraction and elevated levels of clinical biomarkers of myocardial infarction. We conclude that cMyBP-C-AAbs may serve as early predictive indicators of deteriorating cardiac function and patient outcome in acute coronary syndrome patients prior to the infarction. Key Words: acute myocardial infarction, autoantibodies, cardiac myosin binding protein-c, cardiomyopathy

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results